Irritable bowel syndrome

被引:5
|
作者
Joel A. Sach
Lin Chang
机构
[1] UCLA/CURE Neuroenteric Disease Program,
关键词
Irritable Bowel Syndrome; Main Drug Interaction; Irritable Bowel Syndrome Patient; Loperamide; Tegaserod;
D O I
10.1007/s11938-002-0049-3
中图分类号
学科分类号
摘要
Because treatment of irritable bowel syndrome (IBS) patients can be frustrating to the clinician and patient as well, the physician should strive to gain the patient’s confidence with a concise, appropriate work-up and by offering reassurance and education that IBS is a functional disorder without significant long-term health risks.First-line treatment should be aimed at treating the most bothersome symptom.Tricyclic antidepressants are superior to placebo in reducing abdominal pain scores, as well as improving global symptom severity [1••].Loperamide is superior to placebo in managing IBS-associated diarrhea [2••].Whereas fiber has a role in treating constipation, its value for IBS or, specifically, in the relief of abdominal pain or diarrhea associated with IBS is controversial [2••].Although certain antispasmodics have demonstrated superiority over placebo in managing abdominal pain, none of these agents are available in the United States [3••].Probiotic therapy using Lactobacillus plantarum has demonstrated superiority to placebo in improving pain, regulating bowel habits, and decreasing flatulence [4].As studied in a recent placebo-controlled prospective study, Chinese herbal medicines significantly improved bowel symptom scores and global symptom profile, and reduced IBS-related quality of life impairment [5].Some of the most promising emerging therapies in IBS revolve around targeted pharmacotherapeutic modulation of serotonin receptors (ie, 5-HT3 and 5-HT4 subtypes), which are involved in sensory and motor functions of the gut. Other investigational agents that are also being explored include cholecystokinin antagonists, α2-adrenergic agonists (eg, clonidine), serotonin reuptake inhibitors (eg, citalopram), and neurokinin antagonists [6].IBS is best understood through the biopsychosocial paradigm, and therefore, its effective management requires a comprehensive multidisciplinary approach based on patient education and reassurance, enhanced by diet recommendations and lifestyle modifications, and complemented by pharmacotherapy and psychosocial intervention in more severe cases.
引用
收藏
页码:267 / 278
页数:11
相关论文
共 50 条
  • [31] Diarrhea- and constipation-predominant irritable bowel syndrome
    Richard Lea
    Peter J. Whorwell
    Current Treatment Options in Gastroenterology, 2001, 4 (4) : 299 - 308
  • [32] New developments in the diagnosis and treatment of irritable bowel syndrome.
    Longstreth G.F.
    Drossman D.A.
    Current Gastroenterology Reports, 2002, 4 (5) : 427 - 434
  • [33] Current gut-directed therapies for irritable bowel syndrome
    Chang H.Y.
    Kelly E.C.
    Lembo A.J.
    Current Treatment Options in Gastroenterology, 2006, 9 (4) : 314 - 323
  • [34] Irritable bowel syndrome: Update on colonic neuromuscular dysfunction and treatment
    Chey W.D.
    Cash B.D.
    Current Gastroenterology Reports, 2006, 8 (4) : 273 - 281
  • [35] Benefit-Risk Assessment of Tegaserod in Irritable Bowel Syndrome
    Richard Lea
    Peter J. Whorwell
    Drug Safety, 2004, 27 : 229 - 242
  • [36] Subtypes of Irritable Bowel Syndrome in Children and Adolescents
    Self, Mariella M.
    Czyzewski, Danita I.
    Chumpitazi, Bruno P.
    Weidler, Erica M.
    Shulman, Robert J.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2014, 12 (09) : 1468 - 1473
  • [37] Post-infectious irritable bowel syndrome
    Rhodes D.Y.
    Wallace M.
    Current Gastroenterology Reports, 2006, 8 (4) : 327 - 332
  • [38] Post-infectious irritable bowel syndrome
    DuPont A.W.
    Current Gastroenterology Reports, 2007, 9 (5) : 378 - 384
  • [39] Existing and emerging therapies for irritable bowel syndrome
    Acosta, Ruben D.
    Cash, Brooks D.
    EXPERT OPINION ON EMERGING DRUGS, 2011, 16 (02) : 389 - 402
  • [40] New Drugs in the Management of the Irritable Bowel Syndrome
    Michael J. G. Farthing
    Drugs, 1998, 56 : 11 - 21